Enalapril (10 mg/day) in systemic sclerosis: One year, double blind, randomised study (ESS-1): ECG exercise testing - Three months follow-up

Advances in Experimental Medicine and Biology

Volumn 455, Issue , 1999, Pages 285-288

  Bilan, A ^a   Chibowska, M ^a   Palusinski R ^a   Witczak, A ^a   Ostrowski, S ^a   Makaruk, B ^a   Weglarz J ^a   Hanzlik, J ^a   Krasowska, D ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IMMUNOSUPPRESSIVE AGENT; PLACEBO;

ADULT; CARDIOPULMONARY HEMODYNAMICS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROCARDIOGRAM; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; HUMAN; MALE; PHYSICAL CAPACITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC SCLEROSIS; TREADMILL; TREATMENT OUTCOME;

EID: 0033282761     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4857-7_41     Document Type: Conference Paper

References (9)

1. Systemic sclerosis
2. Failure of the circulatory system limits exercise performance in patients with systemic sclerosis
3. Early undifferentiated connective tissue Disease: III. Outcome and prognostic indicators in early scleroderma
4. Altered signal transduction system in hypertrophied myocardium: Angiotensin stimulates collagen synthesis in hypertrophied hearts
5. Evaluation of coronary artery disease by an improved method of exercise electrocardiography: The ST segment/heart rate slope
6. Factors limiting exercise performance in progressive systemic sclerosis
7. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis
8. Drug Therapy: The Management of Chronic Heart Failure
9. Decreased coronary reserve in primary scleroderma myocardial disease